Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-17 | Orexo | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the USIn August 2023, the USPTO granted the first patent for OX640 in the US, providing protection until May 2041. The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term, now extending until November 2042. Orexo has multiple patent applications filed on a global basis and expects to continuously strengthen the patent portfolio for OX640. Nikolaj Sørensen, President and CEO, said: ”Once again, I am pleased with the USPTO recognising the inventiveness of our OX640 product and the AmorphOX technology. This is the eighth patent based on the technology, underscoring its uniqueness and value. In parallel, we continue to broaden the applications of AmorphOX by testing the technology with new substances, which is expected to lead to more patents. The extended exclusivity for OX640 build additional long-term value and improves the attractiveness for potential partners for commercialization in the US market.” For further information, please contact: Orexo AB (publ.) Nikolaj Sørensen, President and CEO Lena Wange, IR & Communications Director About Orexo For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. About AmorphOX® Orexo’s proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. About OX640 OX640 is based on AmorphOX and its powder-based technology provides excellent chemical and physical stability. In addition to providing allergic patients with a more convenient, needle-free alternative to auto-injectors currently on the market, an epinephrine product that provides greater flexibility in relation to how it can be handled and stored should provide significant benefits to patients and healthcare systems worldwide. The information was submitted for publication at 8 a.m. CET, on April 17, 2024. |
||||
2024-04-17 | Orexo | Orexo förstärker patentskyddet i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-02 | Orexo | Orexo meddelar att villkoret för förtida inlösen av sina befintliga obligationer har uppfyllts | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-02 | Orexo | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Orexo | Orexo publishes the Annual and Sustainability Report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Orexo | Orexo publicerar års- och hållbarhetsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-21 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Stärka finanser | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Rättelse: Kallelse till årsstämma i Orexo | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Correction: Notice of Annual General Meeting of Orexo | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Notice of Annual General Meeting of Orexo | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-15 | Orexo | Kallelse till årsstämma i Orexo | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-13 | Orexo | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-13 | Orexo | Orexo har framgångsrikt emitterat seniora säkerställda sociala obligationer med rörlig ränta om SEK 500 m och offentliggör resultatet av återköpserbjudandet avseende sina befintliga obligationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo överväger emission av seniora säkerställda sociala obligationer med rörlig ränta och offentliggör villkorat återköpserbjudande avseende sina befintliga obligationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo stärker sitt hållbarhetsarbete genom att etablera ett socialt finansieringsramverk | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo strengthens its sustainability work by establishing a social financing framework | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-12 | Orexo | Orexo och Sobi avancerar förstudie med AmorphOX | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-12 | Orexo | Orexo and Sobi agree to advance feasibility study with AmorphOX | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-08 | Orexo | Orexo Interim Report Q4 2023, incl. Full Year Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-08 | Orexo | Orexo delårsrapport kv 4 2023, inkl. bokslutskommuniké | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-06 | Orexo | Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-06 | Orexo | Orexos studieresultat för OX640 presenteras vid AAAAI:s Annual Meeting 2024 i Washington, DC, USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-01 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Motvind från valutan | Pressreleaser | Visa Stäng |
|
||||
2023-11-29 | Penser Access | Penser Access: Interview with Orexo - Erik Penser Bank - Nov 29th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-28 | Orexo | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-28 | Orexo | Orexo meddelar att FDA accepterat registreringsansökan för granskning av OX124, ett högdosläkemedel vid opioidöverdos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-06 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 6 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-03 | Penser Access | Penser Access: Går mot lönsamhet, men tillväxten dröjer - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-11-02 | Orexo | Orexo delårsrapport kv 3 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Orexo | Orexo Q3 2023 Interim Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Orexo | Orexo meddelar förändringar i styrelsen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Orexo | Orexo announces changes in the company's Board of Directors | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Orexo:s valberedning inför årsstämman 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Orexo's Nomination Committee for the Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Report from Orexo's extraordinary general meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Kommuniké från Orexo:s extra bolagsstämma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Orexo | Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Orexo | Orexo offentliggör data från MODIA-studien som utvärderar effekten på användning av otillåtna opioider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Orexo | Notice of Extraordinary General Meeting in Orexo AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Orexo | Kallelse till extra bolagsstämma i Orexo AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 2 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-09-18 | Orexo | Orexo lämnar in registreringsansökan till FDA för OX124, ett högdos-läkemedel vid opioidöverdos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Orexo | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Orexo | Orexo deltar i Pareto Securities 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Orexo | Orexo to participate in Pareto Securities' 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Orexo | Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Orexo | Orexo säkrar patentskydd i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-24 | Orexo | Orexo's patent win for ZUBSOLV[®] appealed | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-24 | Orexo | Orexo:s seger i patenttvisten för ZUBSOLV[®] överklagas | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-20 | Penser Access | Penser Access: Det har vänt, men värderingen släpar - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-07-19 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 19 juli 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-07-18 | Orexo | Orexo Q2 2023 Interim Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Orexo | Orexo delårsrapport kv 2 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-03 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 3 juli 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-07-03 | Penser Access | Penser Access: Segrar i patenttvist - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-07-01 | Orexo | Orexo wins patent litigation for ZUBSOLV® in the US | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-01 | Orexo | Orexo vinner patenttvist för ZUBSOLV® i USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Penser Access | Penser Access: Krisvärdering inför viktiga besked - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-05-03 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 2 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-04-27 | Orexo | Orexo Interim Report Q1 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | Orexo | Orexo delårsrapport kv 1 2023 | Rapporter | Ladda ner | Visa Stäng |
|